# Fate Therapeutics Appoints Laura Hamill to Board of Directors
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.fatetherapeutics.com
## Summary

Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical

## Article Body
Accomplished global commercial operations leader brings deep experience launching and scaling biopharmaceutical products as Fate advances its pipeline toward commercialization SAN DIEGO, June 15, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical
## Recent Company News
- 2026-07-06 12:30 EST — [Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-ca-2ca1e01e) — Source: Fate Therapeutics
- 2026-07-01 20:05 EST — [Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences-457e2808) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Appoints Laura Hamill to Board of Directors](https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-congress-of-rheumatology-annual-meeting) — Source: Fate Therapeutics
- 2026-06-25 13:46 EST — [Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting) — Source: Fate Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)